Cartesian Therapeutics

In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary RNA Armory® platform, Cartesian’s internally manufactured portfolio is purposefully designed to be administered conveniently in an outpatient setting without preconditioning chemotherapy. The Company’s portfolio includes its Phase 2 lead asset, Descartes-08, an autologous anti-BCMA mRNA CAR-T.